Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels

European Journal of Pharmacology
F J KoganJ W Gibb


In previous reports, methamphetamine was shown to depress tyrosine hydroxylase (TH) activity in the rat corpus striatum. To evaluate further the mechanism of this decrease in TH activity, enzyme activity was measured in the rat corpus striatum and substantia nigra after repetitive and single-dose methamphetamine administration. Following repeated doses of methamphetamine, nigral TH activity decreased and reached 45% of controls at 12 hr and returned to normal at 60 hr. Striatal TH activity decreased to 40% of control at 36 hr and returned toward normal at 60 hr. When methamphetamine was administered every 6 hr for 30 hr and then discontinued, nigral TH activity returned toward control levels 4 days prior to recovery of striatal TH activity. Methamphetamine initially increased striatal dopamine levels at 6 hr (170% of control). Dopamine levels then decreased in parallel with striatal TH activity but failed to increase as the enzyme recovered. Concurrent administration of chlorpromazine with methamphetamine prevented the methamphetamine-induced decrease in nigral and striatal TH activity and striatal dopamine levels. The results indicate that the methamphetamine-induced depression of striatal and nigral TH activity may be related...Continue Reading


Jan 1, 1974·Journal of Neurochemistry·V K SinghP L McGeer
Apr 1, 1974·European Journal of Pharmacology·M K Buening, J W Gibb
Mar 1, 1969·Proceedings of the National Academy of Sciences of the United States of America·M J BessonJ Glowinski
Feb 1, 1971·The Journal of Pharmacy and Pharmacology·J Häggendal, A Dahlström
Jul 4, 1970·Nature·A J Mandell, M Morgan
Jan 1, 1970·European Journal of Pharmacology·N E AndénU Ungerstedt
Feb 1, 1968·European Journal of Pharmacology·C Morpurgo, W Theobald
Jun 20, 1968·The New England Journal of Medicine·D E Espelin, A K Done


Sep 19, 2002·Journal of Neuroscience Research·Yong Woo LeeMichal Toborek
Jan 1, 1981·Psychopharmacology·G CassensJ J Schildkraut
Dec 1, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·J W Gibb, F J Kogan
Aug 1, 1995·Molecular Neurobiology·S F AliB Gough
Aug 1, 1995·Molecular Neurobiology·J L CadetC Epstein
Jul 2, 2003·Neurotoxicity Research·Kamisha L Johnson-DavisKristen A Keefe
Mar 20, 2013·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Erick T TatroCristian L Achim
Jan 1, 1987·Pharmacology & Therapeutics·J W LangstonGeorge A Ricaurte
Nov 15, 1995·Toxicology Letters·V D'AlmeidaE A Carlini
Mar 1, 1996·Neurotoxicology and Teratology·K D Acuff-SmithCharles V Vorhees
Mar 17, 2004·Neuroscience and Biobehavioral Reviews·Una D McCann, George A Ricaurte
Sep 3, 2013·Neuroscience Letters·Danielle M Friend, Kristen A Keefe
Jul 25, 1997·Brain Research·J FascianoGeorge A Ricaurte
Nov 28, 2002·Neuroscience·K SriramJ P O'Callaghan
Jun 8, 2002·Toxicology Letters·J ObrockiR Thomasius
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael P Caligiuri, Casey Buitenhuys
Oct 2, 2002·Journal of Neurochemistry·Kamisha L Johnson-DavisKristen A Keefe
Sep 1, 1979·Journal of Neurochemistry·C GonzalezS Fidone
Aug 7, 2008·Genes, Brain, and Behavior·A J Saylor, J F McGinty
May 11, 1992·Annals of the New York Academy of Sciences·George A Ricaurte, Una D McCann
Jul 21, 1998·Annals of the New York Academy of Sciences·A StadlinY K Szeto
Dec 12, 2012·The Journal of Pharmacology and Experimental Therapeutics·Danielle M FriendAshley N Fricks-Gleason
Aug 28, 2010·Environmental Health Perspectives·Layla AitlhadjStephen Richard Stürzenbaum
Aug 7, 2013·Neurotoxicity Research·Danielle M FriendKristen A Keefe
Jan 1, 1989·Psychopharmacology·M J De Vito, G C Wagner
Oct 1, 1989·Neuropharmacology·M J De Vito, G C Wagner
Mar 28, 2009·European Journal of Pharmacology·Jarom E HansonA E Fleckenstein
Dec 17, 2008·Experimental Neurology·Kavita PrasadE K Richfield
Aug 9, 2007·Journal of Neurochemistry·David J Eyerman, Bryan K Yamamoto
Dec 19, 2006·Journal of Neurochemistry·Kurt F HauserPamela E Knapp
Nov 16, 2006·Annals of the New York Academy of Sciences·S TheodoreW F Maragos
Nov 16, 2006·Annals of the New York Academy of Sciences·Karen L Anderson, Y Itzhak
Mar 31, 1998·Brain Research·B A BennettJ J Harp
Oct 7, 2004·Neuropharmacology·G R HansonA E Fleckenstein
May 9, 2002·Biochemical Pharmacology·W F MaragosLinda P Dwoskin
Sep 13, 2005·Pharmacology & Therapeutics·Y Itzhak, Syed F Ali
May 12, 2007·Addiction·Kate Baicy, Edythe D London
Nov 16, 2006·Annals of the New York Academy of Sciences·Michela FerrucciFrancesco Fornai
Feb 19, 2013·Journal of Neurochemistry·Danielle M Friend, Kristen A Keefe
Oct 1, 2013·Pharmacology, Biochemistry, and Behavior·Carrie E WilmouthMichael T Bardo
Jan 8, 2015·Frontiers in Neuroanatomy·Javier Blesa, Serge Przedborski
Aug 2, 2003·Journal of Pharmacological Sciences·Taizo KitaT Nakashima
Mar 31, 2009·Brain Research Reviews·Irina N Krasnova, J L Cadet
Aug 3, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Fang-Jung WanHui-Ching Lin
Jun 22, 2005·Toxicology and Applied Pharmacology·W Slikker, J F Bowyer
Jul 12, 2005·Neuropharmacology·Kristi S RauA E Fleckenstein
Oct 2, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·J L CadetXiaolin Deng
Jan 1, 2012·Brain Sciences·Reem K JanBruce R Russell
Aug 1, 1981·Biological Reviews of the Cambridge Philosophical Society·T Magnuson, C Epstein
Aug 1, 1978·Genetical Research·E M EicherS Gluecksohn-Waelsch
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·J Paul HansenA E Fleckenstein
Sep 26, 2015·Pharmacological Reviews·Esa R KorpiGavin S Dawe
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jie YuanGeorge A Ricaurte
May 20, 2005·The Journal of Pharmacology and Experimental Therapeutics·Jannine G TruongA E Fleckenstein
Jan 30, 2004·The Journal of Pharmacology and Experimental Therapeutics·Kamisha L Johnson-DavisDiana G Wilkins
May 1, 1998·Annals of the New York Academy of Sciences·A StadlinY K Szeto

Related Concepts

Lentiform Nucleus Structure
Depression, Chemical
Substantia Nigra Structure
Tyrosine 3-Monooxygenase
Rats, Laboratory

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here